Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Patritumab deruxtecan by Daiichi Sankyo for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Human Epidermal Growth Factor Receptor...
Patritumab deruxtecan by Daiichi Sankyo for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Squamous Non-Small Cell Lung Cancer....
Patritumab deruxtecan by Daiichi Sankyo for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Head And Neck Squamous Cell...
Patritumab deruxtecan by Daiichi Sankyo for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Oral Cavity (Mouth) Cancer. According...
Patritumab deruxtecan by Daiichi Sankyo for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction....
Patritumab deruxtecan by Daiichi Sankyo for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Human Epidermal Growth Factor Receptor...
Patritumab deruxtecan by Daiichi Sankyo for Non-Small Cell Lung Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Non-Small Cell Lung Cancer. According...
Patritumab deruxtecan by Daiichi Sankyo for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...
Patritumab deruxtecan by Daiichi Sankyo for Metastatic Breast Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Breast Cancer. According to...
Patritumab deruxtecan by Daiichi Sankyo for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC)....
Patritumab deruxtecan by Daiichi Sankyo for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....
Patritumab deruxtecan by Daiichi Sankyo for Epithelial Ovarian Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Epithelial Ovarian Cancer. According to...
Patritumab deruxtecan by Daiichi Sankyo for Peritoneal Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Peritoneal Cancer. According to GlobalData,...
Patritumab deruxtecan by Daiichi Sankyo for Acral Lentiginous Melanoma: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Acral Lentiginous Melanoma. According to...
Patritumab deruxtecan by Daiichi Sankyo for Fallopian Tube Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Fallopian Tube Cancer. According to...
Patritumab deruxtecan by Daiichi Sankyo for Endometrial Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Endometrial Cancer. According to GlobalData,...
Patritumab deruxtecan by Daiichi Sankyo for Cervical Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Cervical Cancer. According to GlobalData,...
Patritumab deruxtecan by Daiichi Sankyo for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...
Patritumab deruxtecan by Daiichi Sankyo for Metastatic Breast Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Breast Cancer. According to...
Risk adjusted net present value: What is the current valuation of Daiichi Sankyo's Patritumab deruxtecan?
Patritumab deruxtecan is a monoclonal antibody conjugated commercialized by Daiichi Sankyo, with a leading Phase III program in Non-Small Cell...